A new frontier in the battle against infant acute lymphoblastic leukemia.
作者信息
Tomizawa Daisuke
机构信息
Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo.
出版信息
Haematologica. 2024 Dec 1;109(12):3838-3840. doi: 10.3324/haematol.2024.285975.
Abstract
摘要
相似文献
1
A new frontier in the battle against infant acute lymphoblastic leukemia.对抗婴儿急性淋巴细胞白血病的新领域。
Haematologica. 2024 Dec 1;109(12):3838-3840. doi: 10.3324/haematol.2024.285975.
2
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.婴儿中 MLL 重排的急性淋巴细胞白血病中 RAS 突变的频率和预后影响。
Haematologica. 2013 Jun;98(6):937-44. doi: 10.3324/haematol.2012.067983. Epub 2013 Feb 12.
3
Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.利用全基因组分析揭示婴儿 B 细胞急性淋巴细胞白血病的细胞起源和临床预后标志物。
Haematologica. 2019 Jun;104(6):1176-1188. doi: 10.3324/haematol.2018.206375. Epub 2019 Jan 24.
4
Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.基于一致免疫表型标准治疗的混合表型急性白血病患儿的预后。
Haematologica. 2010 Jun;95(6):928-35. doi: 10.3324/haematol.2009.014506. Epub 2010 Feb 9.
5
Backtracking childhood leukaemia to birth: A battle of addition.回溯儿童白血病的发病根源：一场加法的较量。
Br J Haematol. 2024 Nov;205(5):1670-1671. doi: 10.1111/bjh.19747. Epub 2024 Sep 5.
6
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.加拿大婴儿急性淋巴细胞白血病（ALL）、亚二倍体ALL及混合表型急性白血病（MPAL）的预后因素与结局：CYP-C的报告
Leuk Lymphoma. 2022 Dec;63(13):3208-3216. doi: 10.1080/10428194.2022.2118536. Epub 2022 Sep 6.
7
Altered brain function in new onset childhood acute lymphoblastic leukemia before chemotherapy: A resting-state fMRI study.化疗前新诊断儿童急性淋巴细胞白血病的脑功能改变：一项静息态功能磁共振成像研究
Brain Dev. 2017 Oct;39(9):743-750. doi: 10.1016/j.braindev.2017.04.014. Epub 2017 May 22.
8
Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia.急性淋巴细胞白血病患儿人疱疹病毒6型基因组的定量分析。
J Med Virol. 2008 Apr;80(4):689-93. doi: 10.1002/jmv.21118.
9
ICU Admission in Children With Acute Lymphoblastic Leukemia in Sweden: Prevalence, Outcome, and Risk Factors.瑞典急性淋巴细胞白血病患儿的重症监护病房收治情况：患病率、结局及危险因素
Pediatr Crit Care Med. 2021 Dec 1;22(12):1050-1060. doi: 10.1097/PCC.0000000000002787.
10
Age- and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic countries.北欧国家按免疫表型划分的儿童白血病年龄和性别特异性发病率。
J Natl Cancer Inst. 2003 Oct 15;95(20):1539-44. doi: 10.1093/jnci/djg064.
本文引用的文献
1
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed -rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.阿扎胞苷作为化疗的表观遗传启动剂，对于新诊断的重排急性淋巴细胞白血病婴儿是安全且耐受性良好的：儿童肿瘤学组试验AALL15P1。
Haematologica. 2024 Dec 1;109(12):3918-3927. doi: 10.3324/haematol.2024.285158.
2
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.Blinatumomab 联合化疗治疗婴儿急性淋巴细胞白血病。
N Engl J Med. 2023 Apr 27;388(17):1572-1581. doi: 10.1056/NEJMoa2214171.
3
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.FLT3 抑制剂 lestaurtinib 联合化疗治疗新诊断的 KMT2A 重排婴儿急性淋巴细胞白血病：儿童肿瘤学组试验 AALL0631。
Leukemia. 2021 May;35(5):1279-1290. doi: 10.1038/s41375-021-01177-6. Epub 2021 Feb 23.
4
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.分层风险治疗急性淋巴细胞白血病患儿：来自 JPLSG MLL-10 试验的报告。
Blood. 2020 Oct 15;136(16):1813-1823. doi: 10.1182/blood.2019004741.
5
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.《国际多中心 III 期随机研究：婴儿急性淋巴细胞白血病采用 Interfant-06 方案治疗的结局》
J Clin Oncol. 2019 Sep 1;37(25):2246-2256. doi: 10.1200/JCO.19.00261. Epub 2019 Jul 8.
6
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).无 SCT 强化化疗治疗婴儿 ALL：COG P9407（队列 3）的结果。
Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.
7
Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.异基因造血干细胞移植在 MLL 基因重排阳性急性淋巴细胞白血病婴儿中的早期应用。
Leukemia. 2015 Feb;29(2):290-6. doi: 10.1038/leu.2014.172. Epub 2014 Jun 3.
8
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.分析造血干细胞移植在缓解期伴有 MLL 基因重排的急性淋巴细胞白血病婴儿中的作用：来自儿童肿瘤协作组的报告。
J Clin Oncol. 2011 Jan 10;29(2):214-22. doi: 10.1200/JCO.2009.26.8938. Epub 2010 Dec 6.
9
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.基于风险的治疗对伴有或不伴有MLL基因重排的婴儿急性淋巴细胞白血病的疗效，重点关注远期效应：日本婴儿白血病研究组两项连续研究（MLL96和MLL98）的最终报告
Leukemia. 2007 Nov;21(11):2258-63. doi: 10.1038/sj.leu.2404903. Epub 2007 Aug 9.
10
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.1岁以下急性淋巴细胞白血病婴儿的治疗方案（Interfant-99）：一项观察性研究和一项多中心随机试验。
Lancet. 2007 Jul 21;370(9583):240-250. doi: 10.1016/S0140-6736(07)61126-X.
Zotero 插件